Dr. Chin is an elected member of the National Academy of Medicine, The Association of American Physicians and the American Society for Clinical Investigation. A dermatologist by training, Dr. Chin conducted research in cancer genomics and cancer biology at Dana Farber Cancer Institute and Harvard Medical School, served on the executive subcommittee of The Cancer Genome Atlas (TCGA) and co-led development of the Firehose pipeline at the Broad Institute. As the founding chair of Department of Genomic Medicine at MD Anderson, Dr. Chin developed cross-cutting capabilities with technologies, data and analytics, including the APOLLO platform to systematize workflows for patient-oriented research, the Translational Research Accelerator (TRA) to integrate longitudinal clinical and research data to democratize evidence-based care. Later, as Chief Innovation Officer of the University of Texas System, Dr. Chin launched Project DOC to incorporate digital technologies in chronic disease management for the underserved. She conceptualized and demonstrated feasibility of REDI (Real-world Education, early Detection and Intervention), a framework to orchestrate technology-enabled care in a digitally connected ecosystem. Presently, Dr. Chin is President and CEO of Apricity Health, a next-generation precision oncology company she co-founded to harness real-world patient data and world-class clinical expertise at points of care to bend the toxicity curve, improve therapy effectiveness, accelerate research and develop next-generation precision medicine.